CPC A61K 31/192 (2013.01) [A61F 5/026 (2013.01); A61K 9/0014 (2013.01); A61K 9/0019 (2013.01); A61K 9/0053 (2013.01); A61K 9/06 (2013.01); A61K 9/08 (2013.01); A61K 9/2013 (2013.01); A61K 9/2068 (2013.01); A61K 9/4875 (2013.01); A61K 31/194 (2013.01); A61K 31/196 (2013.01); A61K 31/381 (2013.01); A61K 31/4035 (2013.01); A61K 31/421 (2013.01); A61K 31/423 (2013.01); A61K 31/436 (2013.01); A61K 31/60 (2013.01); A61K 47/10 (2013.01); A61K 47/14 (2013.01); A61K 47/44 (2013.01); A63B 23/02 (2013.01); A61H 2201/0192 (2013.01); A61H 2201/1614 (2013.01); A61H 2201/1652 (2013.01); A61K 31/19 (2013.01)] | 20 Claims |
1. A pharmaceutical composition comprising:
a) about 10% to 30% of a propionic acid derivative NSAID by weight of the pharmaceutical composition, the NSAID including a free acid of a propionic acid derivative NSAID, a salt of a propionic acid derivative NSAID, a solvate of a propionic acid derivative NSAID, or a solvate of a salt of a propionic acid derivative NSAID;
b) about 5% to about 15% of a liquid polyethylene glycol (PEG) polymer by weight of the pharmaceutical composition;
c) about 20% to about 50% of a hard fat by weight of the pharmaceutical composition, the hard fat comprising a mixture of triglycerides; and
d) about 10% to about 30% of a liquid fat by weight of the pharmaceutical composition, the liquid fat comprising a partially hydrolyzed glycerolipid,
wherein the pharmaceutical composition is formulated to have a melting point temperature in the range of about 25° C. or higher.
|